More QbD Information is Better
This article was originally published in The Gold Sheet
Executive Summary
John Towns, director of global CMC regulatory affairs for Eli Lilly said on Sept. 24 at the joint PDA/FDA regulatory discussion on the ICH Q8 guideline in Washington that if the pharmaceutical industry is unclear about how much information should be put in a QbD filing, "more information is better than less in QbD. Convince your folks that putting in more information will not do you any harm.
You may also be interested in...
Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion
Two Chairs, which uses algorithms to match the right therapists with patients, secured $72m in investment to expand its business.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.